Abstract
Haemostasis is a finely balanced and complex process ideally initiated only in response to disruption of the vascular endothelium as a means of preventing loss of blood from an injured vessel. Deviations from the ideal can lead to serious disease. Firstly, thrombosis, which arises as a consequence of inappropriate platelet-platelet interactions at a region of vessel damaged by atherosclerosis, can lead to occlusion of the affected vessel as in myocardial infarction or stroke. Secondly, loss of the ability of platelets to form aggregates leads to Glanzmanns thrombasthenia (GT) with a tendency to bleed for prolonged periods following injury. Glycoprotein IIb / IIIa (GPIIb / IIIa) plays a major role in the regulation of platelet adhesion and aggregation during haemostasis. Upon platelet activation by an agonist a signalling process is initiated, termed “inside-out” signalling, which gives rise to conformational changes within GPIIb / IIIa. These conformational changes increase the affinity of the receptor for its primary ligand, fibrinogen. Bound fibrinogen then acts as a bridging molecule facilitating the interaction of adjacent platelets. Upon fibrinogen binding GPIIb / IIIa undergoes further conformational changes and through a process termed “outside-in” signalling the receptor signals in to the platelet ultimately resulting in acceleration of the aggregation process. Qualitative or quantitative abnormalities in GPIIb / IIIa give rise to GT, a recessive bleeding disorder, and analysis of affected individuals has provided invaluable insights into the structure / function relationship of this receptor. Due to its critical role in mediating platelet aggregate formation GPIIb / IIIa has become a primary target for the development of antithrombotic agents.
Keywords: platelet glycoprotein IIb/IIIa, thrombosis, haemostasis, atherosclerosis, glanzmann thrombasthenia
Current Pharmaceutical Design
Title: The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis
Volume: 10 Issue: 14
Author(s): John F. Fullard
Affiliation:
Keywords: platelet glycoprotein IIb/IIIa, thrombosis, haemostasis, atherosclerosis, glanzmann thrombasthenia
Abstract: Haemostasis is a finely balanced and complex process ideally initiated only in response to disruption of the vascular endothelium as a means of preventing loss of blood from an injured vessel. Deviations from the ideal can lead to serious disease. Firstly, thrombosis, which arises as a consequence of inappropriate platelet-platelet interactions at a region of vessel damaged by atherosclerosis, can lead to occlusion of the affected vessel as in myocardial infarction or stroke. Secondly, loss of the ability of platelets to form aggregates leads to Glanzmanns thrombasthenia (GT) with a tendency to bleed for prolonged periods following injury. Glycoprotein IIb / IIIa (GPIIb / IIIa) plays a major role in the regulation of platelet adhesion and aggregation during haemostasis. Upon platelet activation by an agonist a signalling process is initiated, termed “inside-out” signalling, which gives rise to conformational changes within GPIIb / IIIa. These conformational changes increase the affinity of the receptor for its primary ligand, fibrinogen. Bound fibrinogen then acts as a bridging molecule facilitating the interaction of adjacent platelets. Upon fibrinogen binding GPIIb / IIIa undergoes further conformational changes and through a process termed “outside-in” signalling the receptor signals in to the platelet ultimately resulting in acceleration of the aggregation process. Qualitative or quantitative abnormalities in GPIIb / IIIa give rise to GT, a recessive bleeding disorder, and analysis of affected individuals has provided invaluable insights into the structure / function relationship of this receptor. Due to its critical role in mediating platelet aggregate formation GPIIb / IIIa has become a primary target for the development of antithrombotic agents.
Export Options
About this article
Cite this article as:
Fullard F. John, The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis, Current Pharmaceutical Design 2004; 10 (14) . https://dx.doi.org/10.2174/1381612043384682
DOI https://dx.doi.org/10.2174/1381612043384682 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelium in Aortic Aneurysm Disease: New Insights
Current Medicinal Chemistry Protective Effects of Incretin Against Age-Related Diseases
Current Drug Delivery Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier
Current Neurovascular Research Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Review of Erectile Dysfunction in Diabetic Animal Models
Current Diabetes Reviews Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Oestradiol Signalling in the Hippocampus
Current Neuropharmacology Pharmacologic Therapy in Growth Hormone Disorders and the Heart
Current Medicinal Chemistry Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacy and Exercise as Complimentary Partners for Successful Cardiovascular Ageing
Current Vascular Pharmacology Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update
Current Vascular Pharmacology Methylphenidate (Ritalin): What Makes it so Widely Prescribed During the Last 60 Years?
Current Drug Therapy Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Antegrade Techniques for Chronic Total Occlusions
Current Cardiology Reviews